World’s Oldest Man

“Methuselah lived 900 years,” says the partial lyric in one song.

The account to which the song refers, is found in the Old Testament book of Genesis, chapter 5, verse 27, which states that, “Altogether, Methuselah lived a total of 969 years, and then he died.” (NIV)

But more recently, the World’s Oldest Man, Masazo Nonaka, who was aged 113, has died overnight. That according to his family, granddaughter Yuko Nonaka, who called the family doctor, who in turn, officially pronounced his death.

Of her grandfather’s death Yuko said in part that, “We feel shocked at the loss of this big figure. He didn’t have any health problem. He went peacefully and that’s at least our consolation.”

In April 2018, the Guinness World Records certified Masazo Nonaka, then aged 112 years and 259 days, as being the World’s Oldest Living Man.

Masazo Nonaka was certified by Guinness World Records as the Oldest Living Man April 2018.

Born July 25, 1905, he grew up in a large family – six brothers, one sister – in his youth was a lumberjack and farmer, married in 1931, and fathered five children. He succeeded his parents in owning and operating Yado Nonaka Onsen, a hot springs inn at the foot of

Are you over 65 & taking statin meds? Know anyone who is? It may not be worth it.

If you’re a prescriber, consider this research. If you’re a patient, or know someone who is, consider this for your, or their well-being.

—//—

Statins Have No Primary CVD Prevention Benefit To Older Patients

Takeaway
Statins offer no benefit for the primary prevention of cardiovascular disease (CVD) in adult patients aged ≥65 y.

Why this matters
“[S]tatins may be producing untoward effects in the function or health of older adults that could offset any possible cardiovascular benefit,” say the study authors.

Study design
Researchers conducted post hoc secondary data analyses of patient data from a randomized, open-label clinical trial (N=2867; age, ≥65 y; 49.4% women; all without evidence of atherosclerotic cardiovascular disease); patients were assigned to either a treatment group receiving pravastatin sodium 40 mg/d or a usual care (UC) group.
Funding: National Heart, Lung, and Blood Institute; AstraZeneca; Bristol-Myers Squibb; Pfizer; National Center for Advancing Translational Sciences; The Stroke Foundation.

Key results
Hazard ratios for all-cause mortality in the treatment group vs the UC group were

Spiritual Food For Thought: Becoming Closer To Heaven

Here’s food for thought for the spiritually minded and religious:

As humans, we are often found despising change.

Honestly, we hate it, and wish it never happened.

We like awakening and knowing our socks & underwear are going to be in the same drawer, in the same dresser, in the same location as yesterday, last week, last month, and last year. There’s comfort in that thought.

And yet, we are found as